ElevateBio raises $525M to advance its cell and gene therapy technologies
Cambridge, Mass-based ElevateBio was founded to bridge the world of academic research study and advancement of cell and gene therapies with that of commercialization and production-scale manufacturing. To this end, ElevateBio is in the service of regular spin-out business creation, with the brand-new entities each focused on a specific therapeutic. The business has actually revealed three such business to date, consisting of AlloVir (in partnership with Baylor College of Medicine), HighPassBio (an endeavor with gene-editing business Fred Hutchinson) and Life Edit Therapeutics (in collaboration with AgBiome).
Cambridge, Mass-based ElevateBio was founded to bridge the world of scholastic research and advancement of cell and gene treatments with that of commercialization and production-scale production. To this end, ElevateBio is in the company of frequent spin-out business creation, with the brand-new entities each focused on a particular restorative. The business has actually announced 3 such companies to date, consisting of AlloVir (in partnership with Baylor College of Medicine), HighPassBio (a venture with gene-editing company Fred Hutchinson) and Life Edit Therapeutics (in partnership with AgBiome).